Last update Feb. 22, 2018
Ergot derivative which is used in the prevention and treatment of postpartum hemorrhage.
It has frequent and serious side effects (nausea, vomiting, headache, hypertension, arrhythmias, angina and infarction) that do not occur with oxytocin, so the latter is preferable to reduce the risk of postpartum hemorrhage.
They have occurred serious poisonings in infants when giving it intramuscularly due to confusion with other medication for newborn (Dargaville 1998).
Data on excretion into breast milk is lacking; the excretion of another product of the same family and similar chemical structure, Methylergometrine, has been shown to be negligible.
It may cause shortening of the duration of breastfeeding (Jordan 2009, Begley 1990) by decreasing the concentration of prolactin and inhibiting lactation (Canales 1976, Shane 1974). These effects have been demonstrated to be much more intense that in the case of Methylergometrine.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
The limited use of ergot derivatives should not cause problems in infants (Hale 2017 p.337). It is advisable to use the lowest effective dose and avoid prolonged use.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM